


Our Technology



Lab Products

Sample Preparation Products

Platinum Labware X-Ray Flux Recycling service of turning used platinum products into new items XCF X-ray Flux **Fusion Machines**




Lab Products

Orbis Mining Pty Ltd 50% Acquisition



Laboratory Jaw Crushers



Laboratory Products Flowchart

Crush raw samples

XRF Analysis

Pulverise sample into fine powder



Dose flux into platinum crucible, add sample



Fuse crucible contents into solid glass bead

Present solid glass bead sample to XRF spectrometer for analysis*

ICP Analysis

Pulverise sample into fine powder



Dose flux into platinum crucible, add sample



Fuse crucible contents, dissolve into liquid solution

Present dissolved liquid sample to ICP spectrometer for analysis*

Fire Assay

Pulverise sample into fine powder

- 1. Fluxing and fusion of the precious metals sample*
- 2. Separation of the slag from the lead precious metals-containing button*
- 3. Cupellation separating precious metals from the lead*
- 4. Analysis of precious metals content*

Photon Assay

1. Present crushed samples to Photon Assay machine for gold analysis*

Platinum Products

Precision Products for Industry









Aerospace Components

Glass Production Bushings

Crystal Growing Vessels

Measurement Instrument Components









Chemical Production Vessels

Laboratory Components

Research and Development

Niche Applications / **Custom Designs**

FY22 H1 Highlights





- Record half-year revenue and profit
- Record quarterly profit before tax of \$2.1m during December Q2
- Very strong demand from mining and industrial customers
- Strong demand for capital equipment products, currently at record order levels
- Completion of 50% acquisition in Orbis Mining Pty Ltd
- Continued R&D investment in new products across all divisions

FY22 H1 Financial Highlights



- Revenue up 24% to \$18.5m vs 1H21
- NPAT up 17% to \$2.8m vs 1H21
- Adjusted PBT up 56% to \$3.7m vs 1H21
- \$1.8m positive operating cashflow
- Orbis Mining Pty Ltd fully consolidated into XRF's accounts with minority interest reflected in profit or loss statement





Half Year Results - Overview



| | Half Year Results | | | Full Year Results | | |
|--------------------------------------|-------------------|-------------|--------|-------------------|-------------|-------------|
| (\$m) | 1H22 | 1H21 | Change | 2021 | 2020 | 2019 |
| Sales revenue | 18.5 | 15.0 | 24% | 31.3 | 29.1 | 29.0 |
| Profit before tax | 3.7 | 3.1 | 19% | 6.8 | 4.5 | 3.2 |
| Adjusted profit before tax* | 3.7 | 2.4 | 56% | 5.9 | 4.2 | 3.2 |
| Net profit after tax | 2.8 | 2.4 | 17% | 5.1 | 3.1 | 2.1 |
| Earnings per share (cents) | 2.1 | 1.8 | 17% | 3.8 | 2.3 | 1.6 |
| Weighted average no. of shares | 134,699,698 | 134,133,506 | | 134,345,542 | 133,825,803 | 133,825,803 |
| | | | | | | |
| Dividends (cents per share) | 0.0 | 0.0 | | 2.0 | 1.4 | 1.0 |
| Dividend payout ratio | - | - | | *60% | 60% | 63% |
| *As a percentage of adjusted NPAT | | | | | | |
| *Adjustments (\$) | | | | | | |
| COVID-19 wages subsidies | - | (700,281) | | (826,629) | (212,729) | - |
| COVID-19 other grants/subsidies | - | (20,000) | | (29,522) | (74,776) | - |
| COVID-19 payroll tax refunds | - | - | | - | (82,837) | - |
| Interest on early loan repayment | - | - | | - | 22,496 | - |
| Redundancy / other employee payments | - | - | | - | 97,328 | - |
| Total adjustments | - | (720,281) | | (856,151) | (250,518) | - |

Balance Sheet



| (\$m) | 1H22 | 2021 | Change |
|-------------------------------|------|------|--------|
| Cash and cash equivalents | 4.6 | 5.3 | (12%) |
| Trade and other receivables | 4.9 | 4.5 | 9% |
| Inventories | 13.4 | 12.5 | 7% |
| Other assets | 0.3 | 0.4 | (18%) |
| Property, plant and equipment | 8.1 | 8.1 | (1%) |
| PPE lease asset | 1.0 | 0.6 | 66% |
| Intangible assets | 16.9 | 15.9 | 6% |
| Deferred tax asset | 1.0 | 1.1 | (4%) |
| Total assets | 50.2 | 48.4 | 4% |
| Trade and payables | | | |
| - platinum loan provisions | 2.7 | 3.8 | (27%) |
| - other items | 4.0 | 3.0 | 37% |
| Debt (short-term) | 0.2 | 0.8 | (77%) |
| Debt (long-term) | 1.6 | 0.0 | 100% |
| Current lease liabilities | 0.5 | 0.4 | 27% |
| Non-current lease liabilities | 0.5 | 0.2 | 126% |
| Income tax liability | 0.2 | 0.6 | (60%) |
| Deferred tax liability | 0.7 | 0.5 | 24% |
| Total liabilities | 10.4 | 9.3 | 12% |
| Total equity | 39.8 | 39.1 | 2% |

- Net cash position of \$2.9m
- \$0.9m of platinum on loan converted to owned inventory asset. Platinum asset remains classified as Inventories. Liability shifts from Platinum Loan Provisions to Debt
- Orbis Mining acquisition movement contributions at 1H22:
 - Trade and other receivables: \$0.1m
 - Inventories: \$1.1m
 - Intangible assets: \$0.9m
 - Trade and payables (other items): \$0.9m

Cash Flow Statements



| (\$m) | 1H22 | 2H21 | 1H21 |
|---|-------|-------|-------|
| Net cash inflow from operating activities | 1.8 | 3.2 | 1.3 |
| Net cash (outflow) from investing activities | (0.9) | (0.3) | (0.4) |
| Net cash inflow/(outflow) from financing activities | (1.5) | (0.3) | (1.9) |
| | | | |
| Cash at start of period | 5.3 | 2.6 | 3.6 |
| Net increase/(decrease) in cash | (0.7) | 2.7 | (1.0) |
| Cash at end of period | 4.6 | 5.3 | 2.6 |

Highlights:


- \$2.1m cash paid out for FY21 dividend (1H21: \$1.65m)
- Conversion of \$0.9m in platinum on loan to owned asset resulted in \$0.9m additional outflow from operating activities and \$0.9m inflow from financing activities

Consumables



| (\$m) | 1H22 | 2H21 | 1H21 | |
|---------------|------|------|------|--|
| Sales revenue | 5.2 | 5.1 | 4.2 | |
| Change in % * | 2% | 21% | 5% | |
| | | | | |
| NPBT | 1.7 | 1.6 | 1.3 | |
| Change in % * | 8% | 25% | 7% | |
| Margin % | 33% | 31% | 30% | |

^{*} Compared to immediately prior half-year period



Overview for 1H22:


- Revenue up 2% on 2H21
- NPBT up 8% on 2H21
- Robust demand from the mining sector driven by production and exploration
- Key production input lithium compounds rising in price due to demand from EV sector. We expect revenue and costs to rise by a double-digit percentage, and no negative impact on margins. Impact to materialise more fully in 2H
- Inventory levels expected to rise by ~\$1.5m by 30 June 2022 as a result of lithium raw material cost increases

Precious Metals



| (\$m) | 1H22 | 2H21 | 1H21 | |
|---------------|------|------|------|--|
| Sales revenue | 8.7 | 7.6 | 6.8 | |
| Change in % * | 15% | 11% | 15% | |
| | | | | |
| NPBT | 1.3 | 1.3 | 1.2 | |
| Change in % * | (1%) | 14% | 73% | |
| Margin % | 15% | 18% | 17% | |

^{*} Compared to immediately prior half-year period



Overview for 1H22:

- Revenue up 15% on 2H21
- NPBT flat on 2H21
- Strong demand from mining and industrial markets
- Margins different this half due to revenue mix (precious metals vs fabrication sales)
- Germany office contributed revenue \$2.8m (1H21: \$1.5m) and NPBT \$233k (1H21: \$29k)
- Robust order book maintained into the 2H with margin % expected to expand

*COVID-19 wages subsidies included in NPBT:

- 1H22: Nil
- 2H21: \$41k
- 1H21: \$321k
- 2H20: \$114k


Capital Equipment



| (\$m) | 1H22 2H21 | | 1H21 | |
|---------------|-----------|------|------|--|
| Sales revenue | 5.1 | 4.6 | 5.0 | |
| Change in % * | 10% | (8%) | 33% | |

| NPBT | 0.6 | 0.7 | 0.8 |
|---------------|-------|------|------|
| Change in % * | (13%) | (6%) | 297% |
| Margin % | 13% | 16% | 16% |

^{*} Compared to immediately prior half-year period



Overview for 1H22:

- Revenue up 10% on 2H21
- NPBT down 13% on 2H21. Normalised \$727k NPBT before Orbis Mining loss, up 13% on 2H21 adjusted NPBT excluding COVID-19 wages subsidies
- Steady level of machine sales during 1H, continuing into 2H with record orders on hand
- 50% acquisition of Orbis Mining Pty Ltd, contributing loss of \$95k in 1H. Loss expected to reverse into profit in 2H due to sales delayed into 2H. Good forward sales momentum from large customers due to growing market reputation
- Moving towards launch of new products in 2H

*COVID-19 wages subsidies included in NPBT:

- 1H22: Nil
- 2H21: \$86k
- 1H21: \$306k
- 2H20: \$93k



Growth Strategy for FY22



- New additional focus of growing Orbis laboratory crusher sales, utilising XRF's sales network and resources
- Continuing our expansion in the Precious Metals Division
- Continue with geographical expansion initiatives
- New product releases from all divisions
- Continue to pursue M&A opportunities. Our targets are complementary manufacturing companies, in the laboratory supply or precious metals sectors
- Work to improve our scale/market cap and the share price

Corporate Overview

| Shareholder | Wealth | EBIT | Earnings Per Share | Dividends Declared Per Share | Share Price | Market Capitalisation |
|-------------|---------------|-----------|-----------------------|------------------------------------|-------------|--------------------------|
| F | inancial Year | \$ | Cents | Cents | Cents | \$ |
| | 2015/16 | 2,318,737 | 1.2 | 0.5 | 18.0 | 24,088,645 |
| | 2016/17 | 982,440 | 0.6 | 0.24 | 17.0 | 22,750,387 |
| | 2017/18 | 1,598,268 | 8.0 | 0.3 | 16.0 | 22,081,257 |
| | 2018/19 | 3,249,762 | 1.6 | 1.0 | 20.0 | 26,765,160 |
| | 2019/20 | 4,602,319 | 2.3 | 1.4 | 24.0 | 32,118,193 |
| | 2020/21 | 6,818,111 | 3.8 | 2.0 | 47.5 | 63,916,519 |
| 18 | February 2022 | | | | 55.0 | 74,688,883 |

Directors

Fred Grimwade – Chairman Vance Stazzonelli – Managing Director David Brown – Non-Executive Director David Kiggins – Non-Executive Director

Shareholders

Board and Management – 14.8% Top 20 – 49.4%

Substantial Shareholders

Michael Karl Korber – 8.1% Private Portfolio Managers – 7.9% D & GD Brown Nominees Pty Ltd – 7.3%

DRP

Please visit www.xrfscientific.com for a copy of the Dividend Reinvestment Plan

Locations

Head Office – Perth Manufacturing – Perth and Melbourne International Sales/Service – Brussels (Belgium), Karstein (Germany) and Montreal (Canada)

Capital Structure

Ordinary shares on issue: 135,797,969 Options: Nil

Contact Information

Tel: (08) 9244 0600 86 Guthrie Street, Osborne Park WA

Vance Stazzonelli – CEO vance@xrfscientific.com

Disclaimer

No responsibility for contents of Investor Presentation

- •To the maximum extent permitted by law, XRF Scientific Limited and representatives:
- •make no representation, warranty or undertaking, express or implied, as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient;
- •accept no responsibility or liability as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient; and
- •accept no responsibility for any errors or omissions from this Investor Presentation whether arising out of negligence or otherwise.

Accuracy of projections and forecasts

•This Investor Presentation includes certain statements, opinions, estimates, projections and forward-looking statements with respect to the expected future performance of XRF Scientific Limited. These statements are based on, and are made subject to, certain assumptions which may not prove to be correct or appropriate. Actual results may be materially affected by changes in economic and other circumstances which may be beyond the control of XRF Scientific Limited. Except to the extent implied by law, no representations or warranties are made by XRF Scientific Limited, its advisers or representatives as to the validity, certainty or completeness of any of the assumptions or the accuracy or completeness of the forward-looking statements or that any such statement should or will be achieved. The forward-looking statements should not be relied on as an indication of future value or for any other purpose.

No offer to sell or invitation to buy

•This Investor Presentation does not, and should not be considered to, constitute or form part of any offer to sell, or solicitation of an offer to buy, any shares in XRF Scientific Limited, and no part of this Investor Presentation forms the basis of any contract or commitment whatsoever with any person.

This Investor Presentation does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not permitted under applicable law. Distribution of this Investor Presentation in or from certain jurisdictions may be restricted or prohibited by law. Recipients must inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. Neither XRF Scientific Limited, its advisers or representatives accept any liability to any person in relation to the distribution or possession of this Investor Presentation from or in any jurisdiction.